Beneficial effects of ginsenoside-Rg1 on ischemia-induced angiogenesis in diabetic mice.

Naiquan Yang, Pengsheng Chen, Zhiwen Tao, Ningtian Zhou, Xiaoxuan Gong, Zhihui Xu, Min Zhang, Dingguo Zhang, Bo Chen, Zhengxian Tao, Zhijian Yang

Index: Acta Biochim. Biophys. Sin. (Shanghai) 44(12) , 999-1005, (2012)

Full Text: HTML

Abstract

Neovascularization and the formation of collateral vessels are often impaired in diabetes mellitus (DM) population compared with non-diabetics. Alterations in vascular endothelial growth factor (VEGF) signaling and endothelial nitric oxide synthase (eNOS) dysfunction have been confirmed to play a crucial role in impaired neovascularization in diabetic mice. Accumulating data have suggested that Rg1, a main component of Panax ginseng, has the ability to promote tubulogenesis of human umbilical vein endothelial cells (HUVECs) in vitro, and that the mechanism involves increased expression level of VEGF as well as increased eNOS activation. Thus, we speculated that Rg1 might also have therapeutic effects on the impairment of neovascularization in diabetic individuals. The aim of the present study was to investigate whether Rg1 could improve angiogenesis in ischemic hindlimb of diabetic mice in vivo. Our data demonstrated that Rg1 treatment resulted in improved angiogenesis in the diabetic ischemic hindlimb, and the potential mechanism might involve increased eNOS activation, upregulated VEGF expression, and inhibited apoptosis. Our results suggest that Rg1 may be used as a novel and useful adjunctive drug for the therapy of peripheral arterial disease in DM.